Horizon Discovery Group plc Presentation at 2019 Cowen Health Care Conference
11 March 2019 - 6:01PM
RNS Non-Regulatory
TIDMHZD
Horizon Discovery Group plc
11 March 2019
Horizon Discovery Group plc
Horizon Discovery to Present at the 2019 Cowen Health Care
Conference
Cambridge, UK, 11 March 2019: Horizon Discovery Group plc (LSE:
HZD) ("Horizon" or "the Group" or "Company"), a global leader in
the application of gene editing and gene modulation technologies,
today announces that Terry Pizzie, Horizon's Chief Executive
Officer, will provide an overview and company update, and host
meetings with investors at the 39(th) Annual Cowen Health Care
Conference.
Details of the presentation are as follows:
Date: Tuesday, March 12, 2019
Time: 11.20-11.50 a.m. EDT (15.20-15.50p.m. GMT)
Location: Nantucket Room, 4th Floor. Boston Marriott Copley Place,
Boston
A live webcast of the presentation will be available to watch
here, and an archived replay accessible after the conference for 90
days.
Investors interested in arranging a meeting with the Company's
management, team during this conference should contact the
conference coordinator, or email Horizon@consilium-comms.com.
ENDS
For further information from Horizon Discovery Group plc, please
contact:
Horizon Discovery Group plc
Terry Pizzie, Chief Executive Officer
Tel: +44 (0) 1223 655 580
Numis Securities Limited (Broker and NOMAD)
Michael Meade / Freddie Barnfield / Duncan Monteith
Tel: +44 (0) 207 260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world
leader in gene editing and gene modulation technologies. Horizon
designs and engineers cells using its translational genomics
platform, a highly precise and flexible suite of DNA editing tools
(rAAV, ZFN, CRISPR, Transposon and base editing) and, following the
acquisition of Dharmacon, Inc., its functional genomics platform
comprising gene knockdown (RNAi) and gene expression (cDNA, ORF)
tools, for research and clinical applications that advance human
health. Horizon's platforms and capabilities enable researchers to
alter almost any gene or modulate its function in human or
mammalian cell-lines.
Horizon offers an extensive range of catalogue products and
related research services to support a greater understanding of the
function of genes across all species and the genetic drivers of
human disease and the development of personalised molecular, cell
and gene therapies. These have been adopted by over 10,000
academic, drug discovery, drug manufacturing and clinical
diagnostics customers around the globe, as well as in the Company's
own R&D pipeline.
Horizon is headquartered in Cambridge, UK, and is listed on the
London Stock Exchange's AIM market under the ticker HZD
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAGGUMWWUPBPUU
(END) Dow Jones Newswires
March 11, 2019 03:01 ET (07:01 GMT)
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024